


**SCHEDULE 6
TO THE PROTOCOL FOR THE COVAX NO-FAULT COMPENSATION PROGRAM
FOR AMC ELIGIBLE ECONOMIES**

**Illustration of the Reporting Period
under the COVAX No-Fault Compensation Program for AMC Eligible Economies¹**



* The Reporting Period for any Patient cannot extend beyond 30 June 2027 (which is the date on which the Program’s application process will come to an end and no further Applications will be accepted by the Administrator).

¹ NOTE: The Program only provides compensation for Vaccines that are listed in Schedule 1 and which have been earmarked for delivery through the COVAX Facility to an AMC Eligible Economy, or to a Humanitarian Agency for use in an AMC Eligible Economy, up to and inclusive of 30 June 2023, as tracked by the Administrator using the Vaccines’ batch or lot numbers. Provided that a Vaccine has been so earmarked, a Vaccine must furthermore be administered to the Patient **before** the Vaccine’s “Scope of Coverage Endpoint”, i.e., within 24 months after the date on which the Vaccine was first put into circulation by the manufacturer in any country, following regulatory approval or an emergency use authorization of that Vaccine by any regulator (that date is found on Schedule 1 to the Protocol). If a Vaccine is administered to a Patient **after** the Vaccine’s Scope of Coverage Endpoint, then an Application will **not** be receivable for compensation under the Program.

**SCHEDULE 6
TO THE PROTOCOL FOR THE COVAX NO-FAULT COMPENSATION PROGRAM
FOR AMC ELIGIBLE ECONOMIES**

How do you calculate the Reporting Period that applies to a Patient?

For each Patient, the Reporting Period depends on the date the Vaccine was administered to the Patient. To calculate the Reporting Period that applies to the Patient, you need to:

1. Determine what is the date of the Scope of Coverage End Point that applies to the Vaccine that was administered to the Patient. This date is listed on Schedule 1 to the Protocol; and
2. Calculate the number of months and days from the Patient's vaccination date (i.e. date that the Vaccine was administered to the Patient) until the date of the Vaccine's Scope of Coverage End Point, and:
 - (i) if the Vaccine was administered to the Patient before 30 June 2024, add another 36 months to establish the Reporting Period that applies to the Patient; **or**
 - (ii) if the Vaccine was administered to the Patient between 30 June 2024 and 30 June 2025, the Reporting Period that applies to the Patient ends on 30 June 2027.

* * * * *